MicroPort CardioFlow Medtech Corporation(微创心通医疗科技有限公司)(the “Company”) is a medical device company in China focusing on research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases, which has several subsidiaries including Shanghai MicroPort CardioFlow Medtech Company Limited (collectively "MicroPort CardioFlow" or "the Group").
Our self-developed first-generation transcatheter aortic valve implantation (“TAVI”) product VitaFlow®; was approved by the NMPA in July 2019 and subsequently commercialized in China in August 2019. Our second generation product VitaFlow Liberty™ was approved by the NMPA in August 2021 in China. Currently VitaFlow Liberty™  is also under clinical trial in Europe,we have applied for CE Mark of VitaFlow Liberty™ on December 2021.


In addition to TAVI products, we are also dedicated to serving the vast but underserved transcatheter mitral valve market, strategically targeting all mainstream viable transcatheter valve therapy options for mitral regurgitation through in-house development and collaboration with our global partners.
MicroPort CardioFlow adheres to the vision of building a people centric enterprise ranking as a global leader of evolving and emerging medical technologies. To save lives of patient, and improve their quality of life is of the uttermost importance to us. We strive to provide integrated therapeutic solutions for patients with heart valve disease. At the same time with a global vision, MicroPort CardioFlow is dedicated in providing high quality therapeutic solutions to patients and physicians across the globe .